Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors
Frederick Arce Vargas, Andrew J.S. Furness, Isabelle Solomon et al. · Immunity · 2017
CD25 is expressed at high levels on regulatory T (Treg) cells and was initially proposed as a target for cancer immunotherapy. However, anti-CD25 antibodies have displayed limited activity against established tumors. We demonstrated that CD25 expression is largely restricted to tumor-infiltrating Treg cells in mice and humans. While existing anti-CD25 antibodies were observed to deplete Treg cells in the periphery, upregulation of the inhibitory Fc gamma receptor (FcγR) IIb at the tumor site prevented intra-tumoral Treg cell depletion, which may underlie the lack of anti-tumor activity previously observed in pre-clinical models. Use of an anti-CD25 antibody with enhanced binding to activating FcγRs led to effective depletion of tumor-infiltrating Treg cells, increased effector to Treg cell ratios, and improved control of established tumors. Combination with anti-programmed cell death protein-1 antibodies promoted complete tumor rejection, demonstrating the relevance of CD25 as a therapeutic target and promising substrate for future combination approaches in immune-oncology.
Cited by 418 works. doi:10.1016/j.immuni.2017.03.013 Open-access PDF
Authors
- Frederick Arce Vargas
- Andrew J.S. Furness
- Isabelle Solomon
- Kroopa Joshi
- Leila Mekkaoui
- Marta H. Lesko
- Enrique Miranda
- Rony Dahan
- Andrew Georgiou
- Anna Śledzińska
- Assma Ben Aïssa
- Dafne Franz Demane
- Mariana Werner Sunderland
- Yien Ning Sophia Wong
- Jake Y. Henry
- Tim O’Brien
- David Nicol
- Ben J Challacombe
- Stephen A. Beers
References
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- Signaling by intrathymic cytokines, not T cell antigen receptors, specifies CD8 lineage choice and promotes the differentiation of cytotoxic-lineage T cells
- Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases
- Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- Induction of Tumor Immunity by Removing CD25+CD4+ T Cells: A Common Basis Between Tumor Immunity and Autoimmunity
- Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses
- Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.
- Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients